The FDA has granted breakthrough therapy designation to AlphaMedixTM (212Pb-DOTAMTATE) for treating adults with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), marking it as the first targeted alpha therapy to receive this status. While this therapy is not yet FDA-approved, the breakthrough therapy designation allows for expedited development and review of promising therapies. The designation is based on positive outcomes from phase 1 and ongoing phase 2 trials, showing the treatment’s safety and efficacy, including a notable overall response rate and manageable side effects. AlphaMedix is a targeted alpha emitter that delivers radiation to tumors with minimal damage to surrounding tissue and is currently in phase 2 development. The FDA’s designation highlights AlphaMedix’s potential as an effective treatment option for patients with metastatic or inoperable somatostatin receptor-expressing GEP-NETs, aiming to offer benefits over existing therapies and underscoring a significant advance in the field of neuroendocrine cancer treatment. Read the press release here, and learn more about the clinical trial here.
About
NETRFThe Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
-
For Researchers
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.